07 March 2024
07 March 2024
THIO treatment after cemiplimab was found to be well-tolerated in a heavily pre-treated population so far.
The challenges and opportunities surrounding Africa becoming a clinical trials global force were discussed on day one of CTS Europe.
The new solution combines iOMEDICO's real-world oncology data and PhaseV's causal ML technology.
The primary goal of the trial is to evaluate the tolerability and safety of ECUR-506 following a single intravenous dose.
In the trial, 94.2% of participants treated with islatravir and lenacapavir maintained viral suppression.
According to the CDC, over 50% of women diagnosed with cervical cancer have never been screened or have not been screened in the last five years.
The company held a session on the second day of the Alzheimer’s Disease and Parkinson’s Disease (AD/PD) Conference 2024, discussing its pipeline.
The responsibility of the healthcare sector to lead net zero initiatives was highlighted during the first day of the ongoing CTS Europe 2024.
Merging industry-leading business intelligence & award-winning journalism, this is an unrivalled opportunity for engagement with B2B professionals across a network of 40+ leading media websites.
Steer your business strategy with key data and insights from our latest market research reports and company profiles. Not ready to buy? Start small by downloading a sample report first.
Give your business an edge with our leading industry insights.
